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Available online xxxxThe next generation of devices for personal healthcare monitoring will comprise molecular sensors to monitor
analytes of interest in the skin compartment. Transdermal devices based on microneedles offer an excellent op-
portunity to explore the dynamics of molecular markers in the interstitial ﬂuid, however good acceptability of
these next generation devices will require several technical problems associated with current commercially
available wearable sensors to be overcome. These particularly include reliability, comfort and cost. An essential
pre-requisite for transdermalmolecular sensing devices is that they can be fabricated using scalable technologies
which are cost effective.
We present here aminimally invasivemicroneedle array as a continuousmonitoring platform technology.Meth-
od for scalable fabrication of these structures is presented. The microneedle arrays were characterised mechan-
ically andwere shown to penetrate human skin undermoderate thumb pressure. Theywere then functionalised
and evaluated as glucose, lactate and theophylline biosensors. The results suggest that this technology can be
employed in the measurement of metabolites, therapeutic drugs and biomarkers and could have an important
role to play in the management of chronic diseases.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Microneedles
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Continuous glucose monitoring (CGM)
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Interstitial therapeutic drugmonitoring (iTDM)1. Introduction
The current generation of wearable devices for personal wellness
monitoring such as the Fitbit (Fitbit), UP3 (Jawbone) and SIM band
(Samsung) comprises a variety of physical sensors thatmeasure param-
eters such as movement, heart rate, electrocardiogram (ECG), galvanic
skin response, bioimpedance, and skin temperature. The next genera-
tion of wearable smart devices will also incorporate non-invasive/min-
imally invasive molecular sensors. The main challenges anticipated for
these smart devices would be similar to the ones faced currently by
the physical sensors particularly in terms of reliability, cost and the eth-
ical issues associated with ownership and use of continuous bio-signal
obtained in real time.
Transdermal devices consisting of microstructures such as hollow
[25], swellable [1,27], coated [8,13,26], and solid microneedles [2,6,14,
24], have been used mainly for vaccine [25], and drug delivery [12,22]
but there is a rapidly growing interest in using them formolecular sens-
ing [4,7,15,17,19,23]. The interstitial ﬂuid (ISF) in the skin compartment
exhibits a dynamic exchange of small to medium sized molecules withtry & Institute of Biomedical
), t.cass@imperial.ac.uk
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0.1016/j.sbsr.2016.10.004capillary blood thereby offering access to analytes withminimal trauma
and in a continuous manner, something that could be potentially of
great clinical utility. The main application where minimally invasive,
continuous measurement is of immense value is in continuous glucose
monitoring for diabetes. However with suitable devices this could also
be extended to lactate monitoring in athletes for performance training,
interstitial therapeutic drugmonitoring aswell as lifestyle related appli-
cations such as help in smoking cessation.
Interstitial ﬂuid has been extensively explored for metabolites such
as glucose and lactate [3,18]. Continuous glucose monitoring (CGM)
has been most intensively studied and there is good clinical evidence
that effective CGM in Type 1 diabetes leads both to a reduced frequency
of hypoglycaemic episodes and lowered HbA1c [21].
Minimally invasive, continuous monitoring of lactate in the intersti-
tial ﬂuid could also offer a more informative measure of this metabolite
that would allow athletes to monitor it during their training rather than
taking a single (venous blood) measurement at the end [9].
The ISF microenvironment also offers a compartment in which to
measure the dynamics of therapeutic drugs and biomarkers during
treatment. There are reports suggesting that there are as many as 80
molecular markers in the skin compartment that show good correlation
with venous blood [20]. A recent study in animals has shown a good cor-
relation between the concentration and dynamics of many drugs in ISF
and venous blood [11]. Therapeutic drug monitoring in the interstitial-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Dose-response curves obtained for glucose, lactate and theophylline. Panel (a) is a
dose-response curve obtained from three working electrodes functionalised with
glucose oxidase entrapped in polyphenol but without an epoxy PU membrane. In panels
(b) and (c) the red curves are for working electrodes coated with epoxy PU membrane
and the black curves are for working electrodes without the membrane. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to
the web version of this article.)
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monitoring of drugs with narrow therapeutic index offers a potential
route to personalisation of medication regimes.
Despite the promise of minimally invasive continuous monitoring,
experience with CGM using some of the approved commercial devices
such as those fromMedtronic (Enlite), Dexcom (G5) and Abbott (Free-
Style Libre) has revealed that their uptake is still b10% despite nearly
two and half decades of research and development [10,16]. This can
be attributed mainly to poor accuracy and precision (giving rise to
many false alarms) and high costs of device manufacture. Current
CGM devices are mostly subcutaneously implanted and hence the em-
phasis has been on long term performance. Our approach has been to
use a minimally invasive microneedle array format where the sensors
can be readily and painlessly inserted and where the cost is sufﬁciently
low that daily replacement is feasible. This could give all the proven
beneﬁts of continuous monitoring at a price comparable to the current
singlemeasurement strips.We report here onmethods used for fabrica-
tion of such microneedle arrays.
To achieve the low cost and scalable manufacture injection molding
of polycarbonate yielded 300-microneedle structures/hour. Mechanical
characterisation of these structures is presented and their functionalisa-
tion to produce glucose, lactate and theophylline biosensors is de-
scribed. The in vitro characterisation of these, as well as in vivo studies
on human skin illustrates their performance.
2. Experimental section
2.1. Materials
Cu\\W, aluminum blocks and hardened stainless steel stamps were
obtained from Erodex, UK respectively. Phenol was obtained from
Sigma-Aldrich, UK. Glucose oxidase (Glucose Oxidase HPS300, Sekisui
Diagnostics (U.K.), Ltd., Units, Activity 239U/mgpowder@ 25 °C, source
Ex Aspergillus niger) and lactate oxidase (Lactate Oxidase II, Sekisui Diag-
nostics (U.K.), Ltd., Units, Activity 41 U/mg powder @ 37 °C, source Ex
Aerococcus vinidans)were employed as the enzymes for glucose and lac-
tate sensors respectively. Xanthine oxidase (Xanthine Oxidase microbi-
al, Sigma Aldrich U.K., N7 U/mg powder) was used for the theophylline
sensor.
2.2. Fabrication of the base microneedle array
Copper–tungsten and stainless steel masters, fabricated using elec-
tric discharge milling (EDM), were then used as electrodes for spark
erosion of aluminum blocks to create molds. The spark erosion was re-
peated up to six times. In one instance, the molds were washed with a
pressurized jet to remove the eroded debris. In another example, the
aluminummold created by EDMwas pressed against a hardened stain-
less steel master. For the injection molding, a hydraulic injection-mold-
ing machine (Victory 28, Engel) was used to manufacture the samples.
The molded parts were manufactured in polycarbonate (Makrolon
OD2015) which was dried at 110 °C for 24 h under vacuum prior to
use. The EDM prepared aluminum master inlay was inserted into the
tool which was designed to produce parts measuring
≈25 × 25 × 2 mm or 25 × 25 × 1 mm. For the manufacturing of the
part, we applied the following conditions to the injection molding pro-
cess: Tm = 270 °C (PC melt temperature), Tw = 80 °C (tool tempera-
ture), vi = 20 cm3 s−1(injection speed), shot volume of 4.4 cm3 and a
cooling time (tc) of 5 s. This resulted in a total cycle time 12 s for each
sample.
2.3. SEM characterisation
The bare devices were sputtered with 50 nm chromium and imaged
using a JEOL 5610 scanning electron microscope.Please cite this article as: S. Sharma, et al., Rapid, low cost prototyping of tra
Sensing Research (2016), http://dx.doi.org/10.1016/j.sbsr.2016.10.0042.4. Mechanical evaluation
2.4.1. Measurement of axial compression force
The effect of applying an axial compression load to the microneedle
array was assessed using an Instron 5866 instrument with a 500 N loadnsdermal devices for personal healthcaremonitoring, Sensing and Bio-
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microneedles facing upwards before applying the desired force through
the movable probe of the Instron compression system. The Instron in-
strument applied pressure on the microneedle arrays using an axial
force (parallel to themicroneedles' axes) at a rate of 1mm/s until the re-
quired force was exerted. Forces ranging from 50 N to 400 N were test-
ed. Scanning electron microscopy of microneedle arrays was obtained
before and after application of the compression load. The height of
each microneedle was measured after testing and the percentage
change in microneedle height calculated.
2.4.2. Measurement of transverse fracture force
The transverse failure forces of microneedle arrays were measured
with the same force station as described above. A thin probe (Agar Sci-
entiﬁc) (2 mm thickness at the tip) was slotted in the clamp and used
for this purpose. It was adjusted to ensure that it pressed orthogonally
against a row of eight microneedles. The probe was moved at a speed
of 1 mm/min. The force required to fracture a single microneedle was
determined by dividing the transverse force required to fracture one
row by the number of microneedles in each row (four). The
microneedle arrays were examined by scanning electron microscopy
prior to and after fracture testing.
2.5. Functionalisation
Bare microneedle arrays were sputtered with chromium (15 nm)/
Platinum (50 nm) to obtain the working electrodes. One of the
microneedle arrays was sputtered with Ag (150 nm), which was modi-
ﬁed to an Ag/AgCl reference electrode by treatingwith a saturated solu-
tion of FeCl3. The working electrodeswere biased against the integrated
Ag/AgCl reference electrodes for electropolymerisation and subsequent
chronoamperometry measurements.
The glucose, lactate and theophylline biosensors described here
were fabricated using an electropolymerisation method. For
electropolymerised polyphenols, the electrode was placed in 50 mM
phenol monomer and 10 mg/mL of GOx/LOx/XOx enzyme dissolved in
100 mM PBS. The pH of the solution was buffered to pH 7.2. Each
cycle comprised of holding the working electrode at 0 V for 20 s,
polarising it to a potential of 0.9 V for 15 min for electropolymerisation
of the ﬁlm. Each cycle was repeated six times to obtain the desired ﬁlm
thickness and enzyme loading.
Using 200 μL of various concentrations of glucose, lactate and the-
ophylline solutions, chronoamperometric measurements were made
over 60 s. From these measurements, dose response curves were ob-
tained for glucose, lactate and theophylline biosensors.
2.6. Optical coherence tomography of microneedles in human tissue
Unfunctionalised devices were sterilized by subjecting them to
25 kGy of Co60 (Synergy Health) before the insertion studies. TheTable 1
Showing the Michaelis-Menten KM constant and the maximum limiting current Imax for the th
Biosensor Enzyme
Theophylline biosensor Xanthine oxidase (7 U/mg)
With epoxy PU membrane
Without membrane
Lactate biosensor Lactate oxidase (41 U/mg)
With epoxy PU membrane
Without membrane
Glucose biosensor Glucose oxidase (239 U/mg)
WE1 no membrane
WE2 no membrane
WE3 no membrane
Please cite this article as: S. Sharma, et al., Rapid, low cost prototyping of tra
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teers by the application of moderate thumb pressure (b10 N) for 60 s.
Optical coherence tomography (details) based has been reportedly
used by several groups to look at the skin penetration [5]. On removal
of the device, OCT equipment (Vivosight, Michelson diagnostics) was
used to look at the penetration of the stratum corneum.
3. Results
3.1. SEM characterisation
The SEM images were analysed for geometry. Each injectionmolded
part was 20 × 20 mmwith a 2 mm thick base and comprising 4 arrays
each of which had 16 microneedles in a 4 × 4 subarray. The individual
microneedles were pyramidal in shape; 1000 μm tall, with a 600 μm
square base and a tip diameter of ~40 μm. The pitch between the
microneedles is 1200 μm.
3.2. Mechanical evaluation
In axial compression tests (n= 4) the microneedles tolerated large
forces without fracture. The reduction of microneedle height increased
non-linearly with increasing applied force. This ranged from 1% for
50 N to 17% for 400 N axial forces. Transverse fracture tests (n = 3)
showed that the force required to fracture one row of fourmicroneedles
was 80 ± 3 N (20 N per microneedle).
3.3. Functional evaluation
The functionalised devices were tested with varying glucose, lactate
and theophylline concentrations using chronoamperometry. From the
chronoamperometry studies the dose response curves were ﬁtted to
the Michaelis-Menten equation (Fig. 1).
As seen from the dose response curves, glucose and lactate concen-
tration as low as 0.5 mM could be easily detected. For the glucose bio-
sensors, the three microneedle electrode arrays within a single device
exhibited Km values of 11.4 ± 2.7 mM, 13.9 ± 5.9 mM and 15.5 ±
9.6 mM. The corresponding Imax values for the three electrodes were
20.3 ± 2.4 μA, 23.6 ± 5.4 μA and 25.5 ± 8.7 μA (Table 1).
The Imax valueswere found to be low for the lactate and theophylline
biosensors. This can be attributed to the low activity of the enzymes
used here (Lactate oxidase 41 U/mg powder and Xanthine oxidase
7 U/mg powder @ 37 °C). With the lactate biosensors, the microneedle
array electrodes exhibited Km values of 3.03 ± 0.9 mM with the
epoxy polyurethane (PU) membrane and 0.7 ± 0.08 mM respectively.
The Imax values for the two electrodes were 2.5 ± 0.2 μA and 0.95 ±
0.06 μA respectively. Similarly, the theophylline biosensors exhibited
Km values of 31 ± 1.22 μM with the epoxy polyurethane (PU) mem-
brane and 13 ± 1.84 μM respectively. The Imax values for the two elec-
trodes were 0.52 ± 0.05 μA and 0.31 ± 0.008 μA respectively.ree biosensors.
Km Imax
31 μM± 1.22 0.52 μA ± 0.05
13 μM± 1.84 0.31 μA ± 0.008
3.03 mM ± 0.9 2.5 μA ± 0.2
0.7 mM ± 0.08 0.95 μA ± 0.06
11.4 mM ± 2.74 20.3 μA ± 2.45
13.9 mM ± 5.9 23.6 μA ± 5.4
15.5 mM ± 9.6 25.5 μA ± 8.71
nsdermal devices for personal healthcaremonitoring, Sensing and Bio-
Fig. 2. (a) Showing image of the polycarbonatemicroneedle array sputteredwith 50 nmplatinum. (b) & (c) Scanning electrochemical microscope images of themicroneedle at 100× and
500×magniﬁcation. (d) Optical coherence tomographic image showing the section of tissue with one embeddedmicroneedle as seen here the microneedle penetrates 800 μmdeep into
the skin. (e) Graphics produced in ImageJ using the 3D Viewer plugin showing a row of the microneedles embedded in the tissue.
4 S. Sharma et al. / Sensing and Bio-Sensing Research xxx (2016) xxx–xxxWhilst the increase in linear range is expected for a mass transport
limiting membrane, it would also be expected to reduce the maximum
current. A possible explanation for the increased limiting currents is that
themembrane reduces the rate of diffusion of hydrogen peroxide away
from the electrode surface, resulting in an increased local concentration
quickly consequently leading to a higher current.
3.4. Insertion test on human skin
The insertion ratio, as determined from the tests (n = 16) in vivo
(human skin) was 100% for very moderate forces (b10 N). Whilst the
SEM of the microneedle arrays following insertion tests conﬁrmed the
structural integrity of the device the OCT images conﬁrm the penetra-
tion of the stratum corneum (Fig. 2).
It is observed that the channels created by penetration of
microneedles collapse on account of the highly elastic nature of the
skin layers therefore OCT was done with device inserted.
4. Conclusions
Next generation wearable devices will carry minimally invasive,
continuous monitoring systems for metabolites, biomarkers and drugs
and will have implications for the better management of both lifestyle
and chronic diseases. We have demonstrated here a scalable (300/
hour) and cost effective approach to fabricating polycarbonate-based
(material cost of 2 pence) microneedle structures with desired geome-
try and mechanical properties. The sterilized structures were tested on
human skin and it was observed that the geometry of the tips allowed
penetration of the stratum corneum and access to the dermal interstitial
ﬂuid by insertion under moderate thumb pressure. The microneedlePlease cite this article as: S. Sharma, et al., Rapid, low cost prototyping of tra
Sensing Research (2016), http://dx.doi.org/10.1016/j.sbsr.2016.10.004arrays could subsequently be functionalised to perform as electrochem-
ical biosensors.
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